Cephalon's Provigil Produces Eye-Opening 40% Off-label Use - CEO Baldino
Executive Summary
About 40% of scripts for Cephalon's narcolepsy therapy Provigil (modafinil) are being written for off-label indications, Cephalon CEO Frank Baldino said at a Burns McClellan/Petkevich & Partners analyst meeting in London Oct. 6.
You may also be interested in...
Cephalon Marketing Under Investigation By Philadelphia U.S. Attorney
The Philadelphia U.S. Attorney's investigation into Cephalon's marketing practices covers the entire commercial life of Provigil
Cephalon Marketing Under Investigation By Philadelphia U.S. Attorney
The Philadelphia U.S. Attorney's investigation into Cephalon's marketing practices covers the entire commercial life of Provigil
Provigil Revamped Marketing Campaign To Launch After FDA Cites Promotions
Cephalon plans to proceed with a new marketing program for Provigil (modafinil) in February after receiving a letter from FDA objecting to many of its current promotional materials for the narcolepsy drug